米非司酮治疗围绝经期子宫肌瘤的临床疗效观察  

To observe the clinical curative effect of mifepristone in the treatment of perimenopausal uterine leiomyoma

作　　者：谢爱亮 

机构地区：[1]广西壮族自治区全州县中医院,广西桂林541500

出　　处：《实用妇科内分泌电子杂志》2014年第5期37-38,共2页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的探究米非司酮治疗围绝经期子宫肌瘤的临床疗效。方法 64例围绝经期子宫肌瘤患者经米非司酮治疗。后经彩色多普勒监测治疗前后子宫及肌瘤体积变化与不良反应情况。结果 59例伴有贫血症状患者用药前平均血红蛋白为(68.3±2.3)g/L,用药后上升至(92.4±4.6)g/L,以P<0.05表示差异有统计学意义;治疗后子宫与子宫肌瘤体积均显著缩小,差异有统计学意义(P<0.05)。结论围绝经期子宫肌瘤经米非司酮治疗,可有效改善预后疗效,值得临床推广。Objective To explore the clinical effect of mifepristone in the treatment of perimenopausal uterine leiomyoma. Methods 64 cases of peri menopause patients with myoma of uterus by mifepristone treatment. And adverse reaction volume before and after the color B ultrasound monitoring treatment of uterine and leiomyoma after change of situation. Results 59 cases associated with anemia hemoglobin medication symptoms in patients withanterior to （68.3±2.3）g/L, after treatment up to （92.4±4.6） g/L, expressed in （P〈 0.05） and the difference was statistically significant; after treatment of uterine and uterine myoma volume were significantly reduced, there were statistically significant differences in P〈0.05. Conclusion Perimenopausal uterine fibroids after mifepristone treatment,can improve the prognosis effect, is worth the clinical promotion.

关 键 词：米非司酮 围绝经期 子宫肌瘤 疗效 

分 类 号：R737.33[医药卫生—肿瘤]